Dravet Syndrome Clinical Trials

11 recruiting

Dravet Syndrome Trials at a Glance

12 actively recruiting trials for dravet syndrome are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in San Francisco, London, and Chicago. Lead sponsors running dravet syndrome studies include Assistance Publique - Hôpitaux de Paris, Encoded Therapeutics, and Cook Children's Health Care System.

Browse dravet syndrome trials by phase

Treatments under study

About Dravet Syndrome Clinical Trials

Looking for clinical trials for Dravet Syndrome? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dravet Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dravet Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

Dravet Syndrome
Ionis Pharmaceuticals, Inc.32 enrolled1 locationNCT07531745
Recruiting
Phase 1Phase 2

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Dravet Syndrome
Encoded Therapeutics47 enrolled10 locationsNCT05419492
Recruiting
Phase 3

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Dravet Syndrome
Longboard Pharmaceuticals160 enrolled97 locationsNCT06660394
Recruiting
Phase 3

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Dravet Syndrome
Stoke Therapeutics, Inc170 enrolled61 locationsNCT06872125
Recruiting

Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents

EpilepsyDravet SyndromeWest Syndrome
Assistance Publique - Hôpitaux de Paris1,000 enrolled11 locationsNCT05126914
Recruiting

Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

Dravet SyndromeTuberous Sclerosis ComplexLennox Gastaut Syndrome
Jazz Pharmaceuticals100 enrolled18 locationsNCT05485831
Recruiting

Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

Dravet Syndrome
Assistance Publique - Hôpitaux de Paris50 enrolled1 locationNCT07251673
Recruiting
Phase 3

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Dravet Syndrome
Epygenix150 enrolled46 locationsNCT04462770
Recruiting
Phase 4

Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

Dravet Syndrome (DS)Children Under 2 Years
University of Colorado, Denver12 enrolled3 locationsNCT06598449
Recruiting

SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom

EpilepsyDravet SyndromeSCN1A
NHS Greater Glasgow and Clyde400 enrolled1 locationNCT06504511
Recruiting

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

CancerLymphomaLeukemia+44 more
Sanguine Biosciences20,000 enrolled1 locationNCT05635266
Recruiting

GABA Biomarkers in Dravet Syndrome

Dravet Syndrome
Cook Children's Health Care System36 enrolled1 locationNCT05651204